| Name | Title | Contact Details |
|---|
Whole Hog Productions is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
StretchLab is a unique wellness concept, offering customized assisted-stretch sessions in a comfortable group setting.
medicadepot.com is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Center of McKinney (MCM) is a growing 260-bed hospital with a 90-year history of serving the health care needs of McKinney and the surrounding communities. Over the past several years, MCM has strengthened its medical foundations by adding two new surgical robots, a newly remodeled labor and delivery suites, a Level III Neonatal Intensive Care Unit (NICU) and an advanced biplane Catheterization (cath) lab to treat heart rhythm disorders. Medical Center of McKinney will be expanding its services to the community with the addition of a new off-campus emergency department at 380 & Custer in 2015.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.